BiotechTube

DS-5565 + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Jun 26, 2015 → Jul 6, 2017

NCT ID
NCT02496884

About DS-5565 + Placebo

DS-5565 + Placebo is a phase 3 stage product being developed by Daiichi Sankyo for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02496884. Target conditions include Fibromyalgia.

What happened to similar drugs?

11 of 20 similar drugs in Fibromyalgia were approved

Approved (11) Terminated (3) Active (9)
✅zonisamideEisaiApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + placeboEli LillyApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + placeboSumitomo PharmaApproved
✅QuetiapineAstraZenecaApproved
✅amitriptyline + quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02496884Phase 3Completed
NCT02318706Phase 3Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
ASP8062 + PlaceboAstellas PharmaPhase 2
35
ASP0819 + PlaceboAstellas PharmaPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine 60 mg + PlaceboShionogiPhase 3
40
zonisamideEisaiApproved
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
42
DuloxetineEli LillyApproved
35
duloxetine hydrochloride + placeboEli LillyApproved
43
duloxetineEli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
Treatment for FibromyalgiaEli LillyPre-clinical
26
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
Eszopiclone + placeboSumitomo PharmaApproved
43